SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Genscript Biotech Corporation (GNNSF) , forward earnings yield 1.81%. PEG 0.43 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
- VALUE (0/100, Fail) — the composite valuation score falls below the 60/100 threshold required to pass.
- Forward P/E 55.3
- PEG Ratio 0.43 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
Overall SharesGrow Score: 54/100 with 3/7 criteria passed.
SharesGrow 7-Criteria Score
✓
HEALTH
83/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — GNNSF
Valuation Multiples
P/E (TTM)0.0
Forward P/E55.3
PEG Ratio0.43
Forward PEG0.43
P/B Ratio0.00
P/S Ratio3.20
EV/EBITDA0.0
Per Share Data
EPS (TTM)$-0.25
Forward EPS (Est.)$0.03
Book Value / Share$0.00
Revenue / Share$0.44
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Forward Earnings Yield1.81%
Dividend Yield0.00%
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2016 |
$0.02 |
$114.74M |
$26.17M |
22.8% |
| 2017 |
$0.02 |
$152.65M |
$26.12M |
17.1% |
| 2018 |
$0.01 |
$231.02M |
$21.22M |
9.2% |
| 2019 |
$-0.05 |
$273.35M |
$-96.91M |
-35.5% |
| 2020 |
$-0.11 |
$390.85M |
$-204.95M |
-52.4% |
| 2021 |
$-0.17 |
$511.06M |
$-347.87M |
-68.1% |
| 2022 |
$-0.11 |
$625.7M |
$-226.85M |
-36.3% |
| 2023 |
$-0.05 |
$839.53M |
$-95.48M |
-11.4% |
| 2024 |
$1.36 |
$601.6M |
$2.96B |
492.3% |
| 2025 |
$-0.25 |
$960.95M |
$-533.62M |
-55.5% |
